Vilga Financial Planning LLC Purchases 6,000 Shares of Veeva Systems Inc. $VEEV

Key Points

• Vilga Financial Planning LLC acquired 6,000 Veeva shares worth approximately $1.71 million, representing about 1% of its portfolio. Institutional investors and hedge funds collectively own 88.2% of Veeva’s stock.
• Analysts remain broadly positive, with 19 Buy, eight Hold, and one Sell rating; the consensus rating is “Moderate Buy” with an average price target of $284.88.
• Veeva reported quarterly earnings and revenue above expectations, with revenue up 17.6% year over year. However, the stock was trading near its 52-week high, while insider selling and valuation could pose near-term risks.

Vilga Financial Planning LLC acquired a new stake in Veeva Systems Inc. (NYSE:VEEV - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 6,000 shares of the technology company's stock, valued at approximately $1,713,000. Veeva Systems comprises about 1.0% of Vilga Financial Planning LLC's investment portfolio, making the stock its 25th biggest holding.

Other large investors also recently made changes to their positions in the company. LifeGoal Investments LLC acquired a new stake in Veeva Systems in the 3rd quarter valued at approximately $259,000. GAMMA Investing LLC raised its stake in shares of Veeva Systems by 33.1% during the third quarter. GAMMA Investing LLC now owns 7,499 shares of the technology company's stock valued at $2,141,000 after purchasing an additional 1,867 shares in the last quarter. Professional Advisory Services Inc. acquired a new position in Veeva Systems during the 3rd quarter valued at about $243,000. Farther Finance Advisors LLC boosted its holdings in shares of Veeva Systems by 2.0% in the third quarter. Farther Finance Advisors LLC now owns 12,439 shares of the technology company's stock valued at $3,551,000 after acquiring an additional 249 shares in the last quarter. Finally, Sapient Capital LLC bought a new stake in Veeva Systems during the third quarter worth approximately $268,000. Institutional investors and hedge funds own 88.20% of the company's stock.

Analysts Set New Price Targets

VEEV has been the topic of several recent research reports. Truist Financial lifted their price objective on shares of Veeva Systems from $262.00 to $305.00 and gave the stock a "buy" rating in a research note on Thursday, August 27th. Wells Fargo & Company reaffirmed an "overweight" rating and set a $330.00 target price on shares of Veeva Systems in a research report on Tuesday, September 8th. Oppenheimer boosted their price objective on Veeva Systems from $225.00 to $300.00 and gave the stock an "outperform" rating in a report on Monday, August 17th. Robert W. Baird lifted their target price on shares of Veeva Systems from $260.00 to $300.00 and gave the stock an "outperform" rating in a research report on Thursday, August 27th. Finally, Guggenheim upped their price target on shares of Veeva Systems from $276.00 to $310.00 and gave the company a "buy" rating in a research report on Thursday, August 27th. Nineteen research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $284.88.

Key Veeva Systems News

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva Basics adoption is accelerating. More than 175 emerging biotechs have standardized on Veeva Basics, which offers preconfigured applications spanning clinical, regulatory, quality, medical, and commercial operations. The customer count supports Veeva’s strategy of landing smaller biotech companies early and expanding with them as they grow. Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
• Positive Sentiment: Clinical data automation is scaling. Veeva’s Development Quality Suite has processed data for more than 1 million clinical-trial subjects across over 1,000 studies. The adoption demonstrates expanding use of Veeva’s software in critical research workflows and reinforces the company’s data and switching-cost advantages. Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
• Positive Sentiment: AI and industry visibility are supporting the investment case. Veeva’s upcoming R&D and Quality Summit will feature major customers including Eli Lilly, Pfizer, Sanofi, and UCB, highlighting AI innovations and more efficient drug development. Separately, technical coverage says VEEV is approaching potential buy points after nearly doubling, suggesting renewed institutional interest and strong momentum. Veeva Summit to Showcase AI Innovations
• Neutral Sentiment: Valuation and momentum warrant caution. Analysts describe Veeva as a sticky, mission-critical platform for pharmaceutical customers, but the stock has already rebounded substantially and is trading near its yearly high. Further gains may depend on evidence that AI features, customer additions, and expansion are translating into faster revenue and earnings growth.
• Negative Sentiment: Insider selling and mixed commentary are potential headwinds. Insider Daniel Rizzo sold 4,841 shares, while Jim Cramer expressed a preference for Salesforce over Veeva among software recovery plays. These developments do not change the operating outlook but could encourage profit-taking after the recent advance. Veeva Systems Insider Share Sale

Veeva Systems Price Performance

NYSE VEEV opened at $284.78 on Friday. The firm has a market capitalization of $46.11 billion, a price-to-earnings ratio of 46.84, a price-to-earnings-growth ratio of 1.21 and a beta of 0.93. The company has a 50 day simple moving average of $259.17 and a 200-day simple moving average of $202.93. Veeva Systems Inc. has a 52-week low of $148.05 and a 52-week high of $303.39.

Veeva Systems (NYSE:VEEV - Get Free Report) last released its quarterly earnings data on Wednesday, August 26th. The technology company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.23 by $0.12. The firm had revenue of $927.96 million for the quarter, compared to analyst estimates of $905.38 million. Veeva Systems had a net margin of 29.34% and a return on equity of 14.25%. The company's revenue for the quarter was up 17.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.99 EPS. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, analysts predict that Veeva Systems Inc. will post 6.7 EPS for the current year.

Insider Activity at Veeva Systems

In other Veeva Systems news, EVP Daniel Rizzo sold 4,841 shares of the company's stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $276.51, for a total value of $1,338,584.91. Following the transaction, the executive vice president directly owned 7,665 shares of the company's stock, valued at $2,119,449.15. This represents a 38.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Priscilla Hung sold 750 shares of the firm's stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $261.04, for a total value of $195,780.00. Following the sale, the director directly owned 3,242 shares of the company's stock, valued at $846,291.68. This trade represents a 18.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 51,591 shares of company stock valued at $13,355,945. Insiders own 10.60% of the company's stock.

About Veeva Systems

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company's product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.